Our work at Nature Immunology on a new way of cell therapy engineering. Proud of 1st author Ariel & team. Special Tx to Dr. Levchenko. Yale University Yale UniversityGenetics Yale UniversityCancer Yale UniversityWestCampus Yale UniversityData Yale UniversityMed nature.com/articles/s4159…

Excited to see some of my thesis work finally published in PLOS Biology!Wouldn’t have been possible without Craig Wilen Jin Wei Mia Madel Alfajaro Kadoch Lab Ajinkya Patil Scott Biering Patrick Hsu Silvana Konermann Qin Yan John Doench Ryan Chow Wesley Cai, PhD & more.

Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade dlvr.it/SmVX38

An analysis of CRISPR screening data from our lab and others, and analyses of ICB-treated patient cohorts, shows that mutations in IFN signaling genes generally do not cause resistance to ICB. This agrees with work from Andy Minn and our group: nature.com/articles/s4159…

So grateful and overjoyed that Ryan Chow and I will be continuing our physician-scientist training at Penn Medicine! Thank you so much to all our mentors at Yale School of Medicine Yale MDPhD Program Yale Department of Immunobiology Yale Department of Genetics Yale Dermatology Yale Cancer Center for their support! #Match2023

My favorite study from this past year. What a good way to end our MD PhD time together Yale School of Medicine. We challenge the idea that mutations in IFN pathways are always a protective feature of tumors against immunotherapy. Lots to more to learn and to model for the future.

From the February issue—
Distinct Mechanisms of #MismatchRepair Deficiency Delineate Two Modes of Response to PD-1 #Immunotherapy in #EndometrialCarcinoma , by Ryan Chow et al.
bit.ly/3K96zhv
Yale School of Medicine

So excited to share our work mentored by William Damsky MD, PhD in JID Innovations using cytokine biomarkers to distinguish psoriasis and eczema on acral skin! doi.org/10.1016/j.xjid… (1/n)

In a phase II trial of pembrolizumab in 24 pts with endometrial cancer & either mutational dMMR (n=6) or epigenetic dMMR (n=18), the ORRs were 100% & 44%, respectively; mPFS and mOS were longer in pts with mutational dMMR: aacrjournals.org/cancerdiscover… #GynCSM #ImmunoOnc #medonc

We discover that not only that having a MMR deficiency is an important prognostic factor, but also HOW that deficiency occurs is very important. Check this out this great explanation by Bill Hathaway news.yale.edu/2022/10/27/why…

Now online in Cancer Discovery: Distinct Mechanisms of #MismatchRepair Deficiency Delineate 2 Modes of Response to PD-1 #Immunotherapy in #EndometrialCarcinoma by Ryan Chow Tai Michaels Prof. Akiko Iwasaki eric hoyeon song, Alessandro Santin, et al. Yale School of Medicine Yale Cancer Center aacrjournals.org/cancerdiscover…

Published today in Cancer Discovery: Yale Cancer Center researchers discover for the first time ever, differences in response for #endometrial #cancer treated with #pembrolizumab bit.ly/3f955Xx. #gynsm Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp